N1VO34.SA Novo Nordisk A/S
- Market cap
- BRL 992B
- P/E
- 10.9x
- P/B
- 5.38x
- ROE
- 62.9%
- Dividend yield
- 2.81%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is N1VO34.SA undervalued?
Graham numberN1VO34.SA trades 61.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novo Nordisk A/S fundamental analysis
No fundamental analysis for Novo Nordisk A/S yet.
Novo Nordisk A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone repla…
Full company profileNovo Nordisk A/S financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Novo Nordisk A/S annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 112B | 122B | 127B | 141B | 177B | 232B | 290B | 309B | 351B |
| Gross Profit | 94.2B | 102B | 106B | 117B | 149B | 196B | 247B | 256B | 289B |
| Operating Income | 47.2B | 52.5B | 54.1B | 58.6B | 74.8B | 103B | 128B | 128B | 173B |
| EBITDA | 51.6B | 54.4B | 59.3B | 65.4B | 76.8B | 115B | 137B | 149B | 195B |
| Net Income | 38.6B | 39.0B | 42.1B | 47.8B | 55.5B | 83.7B | 101B | 102B | 139B |
| EPS | 16 | 16 | 18 | 21 | 14 | 19 | 23 | 23 | 31 |
| Balance Sheet | |||||||||
| Total Assets | 111B | 126B | 145B | 195B | 241B | 314B | 466B | 543B | 595B |
| Total Liabilities | 58.9B | 68.0B | 81.6B | 124B | 158B | 208B | 322B | 349B | 374B |
| Shareholders' Equity | 51.8B | 57.6B | 63.3B | 70.7B | 83.5B | 107B | 143B | 194B | 221B |
| Cash & Short-term Investments | 15.6B | 15.5B | 12.1B | 16.4B | 23.1B | 29.4B | 25.4B | 27.0B | 44.5B |
| Cash Flow | |||||||||
| Operating Cash Flow | 44.6B | 46.8B | 52.0B | 55.0B | 78.9B | 109B | 121B | 119B | 159B |
| Capital Expenditure | 9.64B | 8.93B | 5.83B | 6.34B | 14.8B | 38.9B | 51.3B | 90.1B | 49.7B |
| Free Cash Flow | 32.2B | 35.6B | 29.9B | 47.6B | 64.1B | 70.0B | 69.7B | 29.0B | 109B |
| Ratios | |||||||||
| ROE | 74.5% | 67.6% | 66.5% | 67.5% | 66.5% | 78.5% | 70.4% | 52.8% | 62.9% |
| ROA | 34.9% | 31.0% | 29.1% | 24.6% | 23.0% | 26.6% | 21.7% | 18.9% | 23.4% |
| Net Profit Margin | 34.5% | 31.9% | 33.2% | 33.9% | 31.4% | 36.0% | 34.8% | 33.1% | 39.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Novo Nordisk A/S dividends
- Dividend yield
- 2.81%
- Forward dividend
- 0.82 BRL
- Payout ratio
- 50.5%
- Ex-dividend date
- Aug 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | DKK 51.8B | 12 | 50.5% |
| 2024 | DKK 44.1B | 9.94 | 43.7% |
| 2023 | DKK 31.8B | 7.13 | 38.0% |
| 2022 | DKK 25.3B | 6.39 | 45.6% |
| 2021 | DKK 21.5B | 9.31 | 45.1% |
| 2020 | DKK 20.1B | 8.56 | 47.8% |
| 2019 | BRL 19.4B | 8.09 | 49.8% |
| 2018 | BRL 19.0B | 7.77 | 49.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Sep 20, 2023.
Who owns Novo Nordisk A/S
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 26.7B
- Free float 3.15B
Novo Nordisk A/S company profile
- Company name
- Novo Nordisk A/S
- Ticker
- N1VO34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 66,700
- Fiscal year end
- December
- Address
- Novo Alle 1, Bagsvaerd, Denmark, 2880
- Phone
- 45 44 44 88 88
- Website
- novonordisk.com
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S management
10- Mr. Karsten Munk KnudsenExecutive VP, CFO & Member of the Management Board · born 1971
- Mr. Maziar Mike Doustdar B.A.President, CEO & Member of the Management Board · born 1970
- Dr. Martin Holst LangeEVP of R&D, Chief Scientific Officer and Member of the Management Board · born 1970
- Ms. Tania SabroeEVP of People, Organisation and Corporate Affairs & Member of Management Board · born 1977
- Ms. Thilde Hummel BogebjergExecutive VP of Enterprise IT & Quality and Member of Management Board · born 1982
- Mr. Michael NovodSenior VP & Head of Investor Relations · born 1979
- Mr. Robin EversSenior Vice President of Medical Affairs, Regulatory and Safety · born 1970
- Ms. Xia-Ping ZhouSenior VP & President of China
- Frederik KierSenior Vice President of Global Obesity Unit
- Mads Frederik RasmussenSenior VP & Head of Clinical Drug Development